Sarah Hanson-Young says Coalition needs to fix the draft code to save public interest journalism and if it did Greens could back it Dublin, Sept. 14, 2020 (GLOBE NEWSWIRE) — The “Global Regenerative Medicine Market Analysis & Forecast to 2025; Stem Cells, Tissue Engineering,… November ballot measures could result in over a third of Americans having access to legal weed.
The Greens have signalled they could support a code to force Google and Facebook to pay for the value they receive from the distribution of Australian journalism if it is extended to cover the ABC, and if the Coalition comes up with a rescue package for the news wire service AAP.
Its communications spokeswoman, senator Sarah Hanson-Young, told Guardian Australia the Greens were reserving their position until they saw the Morrison government’s legislation but said: “If the government wants to save journalism in Australia, then they need to deliver more than a sugar hit to Murdoch.
“The code as it is is incomplete, and it needs to be fixed if it is to pass the parliament and save public interest journalism.
“The ABC is Australia’s most trusted news source and there is no excuse for locking them out of any arrangements that force the tech giants to pay their fair share.
“The ABC has been a punching bag of this government for too long. Fixing this code, including the public broadcasters and saving AAP, is what Australia’s news landscape requires.”
The signal comes as Facebook and Google have engaged in a major lobbying effort to persuade parliamentarians not to support the Australian Competition and Consumer Commission (ACCC) draft code for digital platforms.
The code aims to address the imbalance in bargaining power between the news media and tech giants and force the platforms to pay for the value they receive from use of Australian journalism.
It would also require Google and Facebook to provide media companies with information on changes that might affect their traffic, such as alterations to news rankings or the search algorithm. If they fail to comply, they could be forced to pay hundreds of millions of dollars in fines.
The ACCC was asked to develop the mandatory code in April by the treasurer, Josh Frydenberg, after negotiations between the digital platforms, the ACCC and media companies stalled, and media companies experienced a sharp fall in ad revenue due to Covid-19.
Google and Facebook say the code is unworkable.
The ABC and SBS are outside the proposed code.
The communications minister, Paul Fletcher, has signalled that is unlikely because the publicly funded broadcasters do not rely on advertising revenue. Fletcher has said the ABC and SBS “have secure government funding, and accordingly the ABC and SBS are not the policy focus when it comes to remuneration aspects of the proposed mandatory code”.
In signalling preparedness to negotiate on the code, Hanson-Young pointed to the importance of AAP in supporting independent journalism in Australia. AAP provides news copy and photographs to news outlets, which is an important service given major media players have all downsized because of ongoing threats to the viability of the industry.
In early August a slimmed-down AAP began its new life after the 85-year-old news wire was saved at the 11th hour by a team of 35 investors and philanthropists after major shareholders News Corp Australia and Nine Entertainment pulled out.
But it remains under financial pressure and it is appealing to the public for help. AAP’s chief executive, Emma Cowdroy, has told Guardian Australia some clients have signed for “much shorter periods” as they may be “testing the service and they also know there is a new entrant coming into the market”.
“It’s probably fair to say that things have been a lot tougher than we thought,” Cowdroy said.
Author: Katharine Murphy
Global Regenerative Medicine Market is Forecast to Grow to Over $124 Billion by 2025, with a CAGR of 23.3% Between 2019 and 2025
Dublin, Sept. 14, 2020 (GLOBE NEWSWIRE) — The “Global Regenerative Medicine Market Analysis & Forecast to 2025; Stem Cells, Tissue Engineering, BioBanking & CAR-T Industries” report has been added to ResearchAndMarkets.com’s offering.
Regenerative medicine’s main objective is to heal and replace organs/cells that have been damaged by age, trauma or disease. Congenital defects can also be addressed with regenerative medicine. Therefore, it’s market encompasses dermal wounds, cardiovascular disease, specific cancer types and organ replacement. To that end, regenerative medicine is a broader field and manipulates the body’s immune system and regeneration potential to achieve its requirement. Financially speaking, investment into this space is dominated by grants, private investors and publicly traded stocks. Looking forward, the regenerative medicine market is promising for a number of robust reasons including:
- Increasing number of potentially successful clinical trials
- Increasing number of mergers and acquisitions
- High unmet need in many indications
- Global penetration, especially in Japan will boost the market
Of course, restrictions to this market include strict regulations in certain geographies, and also the level of investment required to support R&D, clinical research, trials and commercialization. Reimbursement strategies are also paramount to the success of the overall space.
This report provides a comprehensive overview of the size of the regenerative medicine market, segmentation of the market (stem cells, tissue engineering and CAR-T therapy), key players and the vast potential of therapies that are in clinical trials. The analysis indicates that the global regenerative medicine market was worth $35 billion in 2019 and will grow to over $124 billion by 2025, with a CAGR of 23.3% between this time frame. This report describes the evolution of such a huge market in 15 chapters supported by over 350 tables and figures in 700 pages.
- An overview of regenerative medicine that includes: stem cells, allogenic and autogenic cells, umbilical cord blood banking, tissue engineering and CAR T therapies.
- Global regenerative medicine market, global breakdown, application breakdown and leading market players
- Detailed account of the stem cell industry market by geography, indication and company profiles
- Profiles, marketed/pipeline products, financial analysis and business strategy of the major companies in this space
- Focus on current trends, business environment, pipeline products, clinical trials, and future market forecast for regenerative medicine
- Insight into the challenges faced by stakeholders, particularly about the success vs. failure ratios in developing regenerative medicine drugs and therapies.
- Insight into the biobanking industry globally and its impact on the overall market
- Description and data for the prevalence of disease types that are addressed by regenerative medicine, stem cells, tissue engineering and CAR-T therapies
- Financial market forecast through 2023 with CAGR values of all market segments outlined in the objective
- SWOT analysis of the global market
- Geographical analysis and challenges within key topographies including the USA, Japan, South Korea, China and Europe
1.0 Report Synopsis
3.0 Stem Cells and Clinical Trials
4.0 Stem Cells, Disruptive Technology, Drug Discovery & Toxicity Testing
5.0 Stem Cell Biomarkers
6.0 Manufacturing Stem Cell Products
7.0 Investment & Funding
8.0 Regenerative Medicine Market Analysis & Forecast to 2025
9.0 Stem Cell Market Analysis & Forecast to 2025
10.0 Tissue Engineering Tissue Engineering Market Analysis and Forecast to 2025
11.0 Biobanking Market Analysis
12.0 Global Access & Challenges of the Regenerative Medicine Market
13.0 Cell and CAR T Therapy
14.0 Company Profiles
15.0 SWOT Industry Analysis
- Astellas Institute for Regenerative Medicine (Ocata Therapeutics)
- Baxter International (Baxalta, Shire)
- Caladrius Biosciences (NeoStem)
- CHA Biotech
- Cynata Therapeutics
- Cytori Therapeutics
- Genzyme (Sanofi)
- InCyte Corp
- Millennium Pharmaceutical
- Osiris Therapeutics
- Pluristem Therapeutics
- SanBio Current Stem Cell Trials
- Seattle Genetics Current Stem Cell Trials
- StemCells Inc
- STEMCELL Technologies
- Takara Bio
- Teva Current Stem Cell Trials
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.
Author: Research and Markets
States plow forward with pot, with or without Congress
The biggest stakes are in New Jersey and Arizona, where polling suggests voters will back recreational sales.
If both measures pass, more than 16 million additional Americans would be living in states where anyone at least 21 years old can buy weed for any reason. That would mean more than 100 million Americans would have access to legal recreational marijuana sales, less than a decade after Colorado and Washington pioneered the modern legalization movement.
South Dakota and Montana could also pass recreational legalization measures this year. The former could become the first state to go from a total ban on weed to legalizing both medical and recreational sales, if voters back a pair of referendums.
Meanwhile, Mississippi voters will decide whether to legalize medical marijuana. Mississippi would join a recent wave of archconservative states — including Oklahoma, Arkansas and Utah — that have embraced medical sales in recent years.
“We’re now working in very red states,” said Matthew Schweich, deputy director of pro-legalization advocacy group Marijuana Policy Project. “If we win in Mississippi, Montana and South Dakota … it becomes more difficult for those senators to oppose legislation that allows their home states to implement laws the voters have approved.”
If all five states pass their ballot measures, more than two-thirds of federal lawmakers would represent states with legal medical or recreational marijuana markets. Even if only the New Jersey and Arizona measures pass, those votes would add four additional senators and 21 representatives — meaning a quarter of the Senate and a third of the House would represent states with legal adult-use marijuana.
Lawmakers often change their views on cannabis once their state legalizes it, with Sen. Cory Gardner (R-Colo.) being the most obvious example. And this year’s ballot measures would bring in some heavyweight lawmakers. New Jersey Democrat Frank Pallone is the House Energy & Commerce chair and South Dakota Republican John Thune is Senate majority whip.
“Every victory on the state level makes the federal-state conflict more untenable than it already is,” Schweich said.
The Brookings Institution’s John Hudak points out that marijuana legalization referendums have become routine, no longer seen as exotic or outlandish.
“This is just mainstream public policy,” said Hudak, author of “Marijuana: A Short History”. “In the same way that states have votes on tax policy and a variety of other types of issues, this is rapidly becoming just another standard public policy issue.”
Here’s a breakdown of the 2020 marijuana state ballot measures:
New Jersey: Lawmakers in New Jersey already are working on a bill to implement a recreational marijuana ballot question that looks likely to pass. The legislature referred the question to the ballot after an effort to pass a legalization bill narrowly failed last year.
If successful, New Jersey’s market would boast some of the lowest marijuana tax rates in the nation. The state has nearly 9 million residents and is close to major cities including New York and Philadelphia. A legal market would undoubtedly draw consumers from neighboring states and could push others in the region to prioritize legalization over fears of losing tax dollars during a state budget crisis.
Arizona: Four years ago, Arizona voters narrowly defeated a referendum to legalize recreational sales. But they will have an opportunity to reverse course in 2020. Most polling indicates strong support for authorizing taxed, regulated sales. There are more than 250,000 patients enrolled in the state’s medical program — an increase of 150 percent from four years ago. Opponents of the initiative have been badly outspent by the multimillion-dollar, industry-backed legalization campaign. And a legal challenge to the initiative was rebuffed by the courts. If rec sales became reality in Arizona, they would extend a contiguous network of five western states with more than 60 million residents spanning from Canada to Mexico that have full legalization.
But the latest polling data suggests a rapidly tightening contest. Support for legalization is at 46 percent, compared to 45 percent opposition, according to polling from OH Predictive Insights conducted over the last several days.
“Based on the latest numbers, the pro-marijuana folks should put the cork back in the champagne bottle,” said Mike Noble, the polling firm’s managing partner.
MIssissippi: Polling shows strong support for medical marijuana legalization in the state, but activists behind a medical marijuana initiative are contending with challenges on two fronts — campaigning during a pandemic and a competing initiative placed on the ballot by the state legislature.
More than 80 percent of Mississippi voters favor medical marijuana legalization, but they’ll have two measures to choose from when they head to the polls: an activist-driven initiative that collected signatures to make the ballot and one referred by lawmakers that the activists contend is meant to confuse voters and split the vote. Still, a June poll from FM3 Research shows that the activist-led initiative has a 29-percentage-point lead over the alternative.
Montana: Montana, where medical marijuana is already legal, has two measures on the ballot: one to legalize recreational marijuana and another that sets the legal age at 21. Both measures are necessary, but some worry that having two separate initiatives will confuse voters.
Legal marijuana, nonetheless, has the support of a majority of Montanans — 54 percent, according to a February poll from the University of Montana. Pro-legalization group New Approach Montana has raised more than $2.5 million since late June and plans to launch a slew of TV ads in October. The anti-legalization campaign Wrong for Montana, meanwhile, just launched in the last few days.
South Dakota: The state is one of only three remaining states (along with Idaho and Nebraska) that outlaws all forms of cannabis — including use for very specific medical situations such as child seizures. South Dakota will be the first state to put medical and recreational measures on the ballot in the same election. Measure 26 sets up a medical marijuana program, and Amendment A would legalize adult-use marijuana. While it’s unusual, Schweich said they put up both measures at the same time because their polling shows support among South Dakotans for both medical and recreational cannabis.
The Republican-led state government is strongly opposed to all things cannabis. Republican Gov. Kristi Noem even vetoed a hemp legalization law passed by the Republican-led legislature last year, but eventually dropped her opposition this year. The adult-use initiative is constitutional — meaning the legislature could not repeal it if it passes in November. The medical initiative, meanwhile, is statutory. The legislature would have the power to repeal or amend that law, but given that statewide support for medical marijuana, it seems less likely they would interfere if voters approve it.
Covid-19 setbacks: Because of the coronavirus crisis, 2020 isn’t quite the banner year for marijuana legalization that advocates hoped for.
The pandemic derailed efforts to put medical marijuana legalization questions before voters in Idaho and North Dakota. Advocates in Nebraska actually collected enough signatures to make the ballot, but the state Supreme Court ordered the Secretary of State to remove the question.
The public health crisis also upended efforts to put recreational legalization on the ballot in Missouri, Arkansas and Oklahoma, while a similar effort in Florida failed before the pandemic hit.